Antibiotic Recalled

Lupin Pharmaceuticals Inc. is recalling 14,400 bottles of cephalexin for oral suspension USP, 250 mg/5 mL (NDC 68180-441-01), because extraneous material was found between the primary heat-sealed package and the poly-woven bag used as secondary packaging. The recall appeared in the February 6, 2019, US Food and Drug Administration (FDA) Enforcement Report.

The recall affects cephalexin from lot F801282 (Exp. 6/20). The recalled bottles were distributed to five wholesalers, two drug chains, and a supermarket that may have further distributed the product throughout the United States.

Lupin Pharmaceuticals voluntarily initiated the recall January 9, 2019. The FDA designated it Class II January 31, 2019. The classification suggests use of the affected product could cause temporary or medically reversible adverse health consequences. Although the likelihood is remote, a possibility of serious harm also exists.

Cephalexin is a prescription antibiotic used to treat a variety of bacterial infections.

—Jolynn Tumolo

For more Pharmacy Learning Network articles, visit the homepage